surveil
nosocomi
infect
ni
becom
integr
part
infect
control
qualiti
assur
mani
countri
gastmeier
et
al
report
effect
surveil
could
reduc
ni
rate
averag
surveil
program
provid
data
microb
caus
specif
ni
resist
antibiot
moreov
program
guid
clinic
practic
ni
prevent
effort
differ
geograph
region
clinic
set
surveil
infect
dai
intens
care
unit
icu
becom
import
owe
frequent
employ
invas
advanc
life
support
devic
especi
introduct
surviv
sepsi
bundl
nevertheless
accord
three
largest
surveil
system
pool
mean
rate
dai
pneumonia
vap
per
central
bloodstream
infect
clabsi
per
urinari
tract
infect
cauti
per
addit
dai
associ
signific
cost
mortal
crude
mortal
rate
icu
patient
dai
moreov
indic
messag
bad
bug
drug
releas
infecti
diseas
societi
america
emerg
antibiot
resist
threaten
exacerb
problem
ni
critic
ill
patient
decreas
suscept
microb
antibiot
well
describ
sever
surveil
studi
past
decad
increas
rate
bloodstream
infect
caus
resist
mdr
bacteria
report
addit
morbid
mortal
rate
increas
studi
prospect
surveil
conduct
determin
dai
rate
preval
antibioticresist
isol
adult
icu
ms
icu
aim
analyz
secular
trend
incid
differ
type
dai
determin
common
pathogen
involv
determin
rate
antimicrobi
resist
overal
mortal
period
studi
conduct
adult
icu
admiss
age
year
older
per
year
locat
major
teach
hospit
northern
part
taiwan
infect
surveil
control
program
establish
one
infect
control
practition
icp
everi
bed
patient
admit
icu
period
develop
infect
hour
admiss
ie
nosocomi
infect
elig
studi
protocol
studi
approv
institut
review
board
teach
hospit
icubas
surveil
conduct
accord
us
center
diseas
control
prevent
cdc
procedur
patient
unit
monitor
ni
affect
particular
bodi
site
infect
one
site
patient
count
separ
infect
antibiot
suscept
pathogen
involv
analyz
data
prospect
collect
least
week
icu
train
icp
accord
standard
protocol
definit
us
cdc
nation
healthcar
safeti
network
nhsn
formerli
nation
nosocomi
infect
surveil
system
nni
dai
outcom
surveil
compon
categor
use
standard
us
cdc
nhsn
definit
includ
laboratori
clinic
criteria
involv
patient
demograph
inform
date
site
infect
du
ratio
pathogen
antimicrobi
suscept
invas
procedur
overal
mortal
crude
mortal
record
report
case
dai
also
verifi
infecti
diseas
specialist
data
also
collect
expos
patient
icu
prospect
hospit
databas
includ
demograph
clinic
characterist
pneumonia
defin
patient
new
progress
infiltr
consolid
cavit
pleural
effus
chest
radiograph
follow
sign
symptom
new
onset
purul
sputum
chang
charact
sputum
vap
categor
ventil
associ
patient
intub
receiv
ventil
hour
prior
develop
pneumonia
detect
vap
microorgan
tracheal
aspir
obtain
via
endotrach
tube
suction
tracheostomi
tube
suction
method
cultur
bloodstream
infect
bsi
defin
patient
recogn
pathogen
cultur
one
blood
cultur
microorgan
cultur
blood
relat
infect
anoth
site
common
skin
contamin
eg
staphylococcu
con
requir
cultur
two
blood
cultur
drawn
separ
occas
least
one
blood
cultur
patient
intravascular
devic
microorgan
tip
cultur
ident
blood
cultur
clabsi
consid
central
cathet
place
hour
secondari
site
infect
present
detect
clabsi
central
cathet
remov
asept
segment
distal
end
tip
cathet
along
pair
peripher
blood
sampl
cultur
central
colon
defin
isol
unit
central
cathet
tip
use
semiquantit
maki
cultur
techniqu
symptomat
uti
defin
patient
one
follow
sign
symptom
recogn
caus
fever
dysuria
urgenc
frequenc
suprapub
tender
patient
posit
urin
cultur
microorgan
per
urin
two
speci
microorgan
pyuria
urin
specimen
white
blood
cell
posit
urin
cultur
cfuml
speci
microorgan
cauti
symptomat
uti
occur
patient
indwel
urinari
cathet
place
within
hour
period
onset
uti
detect
cauti
organ
urin
sampl
asept
aspir
sampl
port
urinari
cathet
cultur
quantit
pathogen
isol
blood
cultur
use
system
becton
dickinson
diagnost
instrument
system
spark
md
usa
use
bactalert
system
inc
marci
l
franc
pathogen
isol
specimen
use
standard
method
specifi
clinic
laboratori
standard
institut
clsi
antibiot
suscept
determin
use
disk
diffus
test
interpret
accord
criteria
specifi
clsi
ni
rate
defin
number
ni
per
patient
day
calcul
number
icu
day
cohort
number
icu
day
onset
ni
infect
rate
calcul
number
infect
specifi
bodi
site
per
devic
day
du
ratio
calcul
number
per
number
secular
trend
du
ratio
antimicrobi
resist
rate
mortal
mortal
rate
analyz
test
linear
trend
overal
dai
rate
analyz
poisson
regress
analysi
logist
regress
stepwis
forward
approach
use
assess
prognost
factor
mortal
control
potenti
confound
variabl
ie
demograph
invas
devic
laboratori
data
odd
ratio
confid
interv
ci
calcul
defin
statist
signific
statist
analysi
conduct
use
epi
infotm
version
releas
us
cdc
graph
secular
trend
mortal
inhospit
mortal
rate
creat
use
sigmaplot
version
systat
inc
san
jose
ca
usa
studi
period
evalu
ni
dai
occur
patient
admit
ms
icu
mean
apach
ii
score
crude
mortal
rate
studi
period
patient
admit
ms
icu
mean
age
year
male
gender
account
length
icu
stay
day
averag
patient
admit
due
major
medic
condit
neoplasm
digest
system
problem
respiratori
system
problem
patient
serum
albumin
gdl
blood
creatinin
mgdl
patient
undergo
hemodialysi
icu
stay
overal
rate
ni
dai
episod
per
episod
per
respect
common
dai
type
cauti
mean
episod
urinari
rang
per
urinari
follow
vap
mean
episod
rang
per
clabsi
mean
episod
central
rang
per
central
du
ratio
mechan
ventil
mean
p
central
line
catheter
mean
central
p
increas
especi
incid
vap
decreas
remain
stabl
p
tabl
figur
total
pathogen
isol
clinic
specimen
tabl
acinetobact
baumannii
pseudomona
aeruginosa
staphylococcu
aureu
three
common
pathogen
associ
vap
aureu
baumannii
candida
albican
account
major
clabsi
contrast
candida
nac
spp
rather
bacteria
common
cauti
pathogen
follow
enterococci
escherichia
coli
rate
antibiot
resist
everi
year
present
tabl
rate
infect
aureu
mrsa
mean
case
patient
aureu
remain
rel
stabl
throughout
studi
period
rate
infect
resist
bacilli
increas
markedli
particularli
antibioticresist
proport
among
enterobacteriacea
infect
increas
significantli
p
includ
klebsiella
pneumonia
mean
case
patient
k
pneumonia
e
coli
mean
case
patient
e
coli
e
coli
mean
case
patient
e
coli
figur
show
three
common
vap
pathogen
percentag
mrsa
mean
case
patient
aureu
p
aeruginosa
irpa
mean
case
patient
p
aeruginosa
baumannii
irab
mean
case
patient
baumannii
tend
decreas
howev
irab
increas
percentag
isol
mrsa
p
irpa
p
isol
irab
p
remain
rel
constant
crude
mortal
rate
crude
mortal
rate
die
patient
rang
die
patient
rang
respect
versu
mortal
rate
three
dai
die
patient
versu
die
patient
vap
die
patient
versu
die
patient
clabsi
die
patient
versu
die
patient
cauti
overal
trend
mortal
rate
show
signific
variat
p
cauti
clabsi
mortal
rate
dai
significantli
differ
p
furthermor
mortal
rate
vap
drop
markedli
mortal
rate
increas
figur
dai
independ
factor
mortal
ci
p
mortal
ci
p
multipl
regress
analysi
signific
prognost
factor
p
mortal
includ
apach
ii
score
servic
length
stay
onset
infect
serum
albumin
blood
creatinin
neoplasm
hemodialysi
tabl
mean
rate
ni
dai
adult
ms
icu
studi
period
much
lower
report
inicc
well
icu
develop
countri
similar
report
hospit
us
cdc
nhsn
slightli
higher
indic
icu
german
surveil
system
icukiss
reason
high
dai
rate
inicc
report
develop
countri
may
includ
resourc
limit
lack
legal
enforc
infect
control
program
poor
adher
infect
control
guidelin
prospect
surveil
infect
control
program
establish
nearli
year
hospit
made
great
effort
control
infect
implement
infect
control
bundl
educ
program
increas
devicerel
infect
obviou
except
cauti
strategi
show
effect
control
dai
rate
suggest
necess
infect
control
bundl
implement
common
pathogen
show
geograph
variat
distribut
baumannii
aureu
p
aeruginosa
three
common
vap
pathogen
studi
us
cdc
nhsn
studi
sentri
antimicrobi
surveil
studi
although
percentag
differ
studi
percentag
isol
mrsa
p
irpa
p
isol
irab
p
remain
rel
constant
howev
variat
percentag
would
statist
signific
might
rather
due
chanc
actual
variat
contrast
higher
rate
baumannii
c
albican
isol
compens
rel
low
rate
con
enterococcu
spp
isol
case
clabsi
c
albican
replac
nac
spp
case
cauti
differ
clinic
set
institut
studi
period
target
popul
specif
infect
type
might
account
part
differ
studi
con
less
frequent
identifi
clabsi
criteria
slightli
differ
us
cdc
definit
bsi
cdc
defin
skin
contamin
bsi
common
skin
contamin
eg
con
cultur
least
one
blood
cultur
patient
intravascular
line
physician
institut
appropri
antimicrobi
therapi
howev
con
bsi
studi
enrol
patient
one
blood
cultur
con
posit
microorgan
cultur
tip
intravascular
devic
also
con
percentag
con
isol
expect
least
aureu
isol
report
previou
studi
howev
frequenc
baumannii
candida
spp
specimen
patient
clabsi
also
report
increas
hospit
taiwan
well
sever
asian
countri
turkey
thailand
although
frequenc
nac
spp
repres
one
candida
spp
also
rise
specimen
patient
cauti
earli
empir
usag
broad
spectrum
antibacteri
agent
critic
ill
patient
preemptiv
administr
fluconazol
common
factor
contribut
increas
frequenc
isol
rel
resist
pathogen
use
indwel
cathet
increas
suscept
resist
pathogen
associ
biofilm
format
high
preval
mrsa
common
problem
worldwid
situat
much
sever
institut
data
show
lower
incid
densiti
aureu
higher
proport
mrsa
percentag
mrsa
infect
inicc
report
us
cdc
nhsn
report
region
sentri
antimicrobi
surveil
program
report
tigecyclin
evalu
surveil
trial
test
report
mrsa
rate
decreas
mani
european
countri
usa
sever
ill
patient
frequent
use
antibiot
might
account
part
high
rate
mrsa
isol
patient
icu
major
teach
hospit
anoth
possibl
explan
clonal
spread
resist
gene
resist
strain
molecular
analysi
need
prove
hypothesi
accord
infect
control
polici
icu
patient
admit
icu
resist
mdr
checklist
use
inquir
mdr
pathogen
includ
mrsa
infect
colon
mrsa
isol
contact
precaut
implement
furthermor
promot
activ
present
infect
control
team
also
carri
nonwarn
investig
handwash
isol
precaut
season
give
feedback
result
unit
infecti
diseas
doctor
assist
carri
infecti
diseas
treatment
antibiot
use
icu
mrsa
infect
rate
reduc
year
interestingli
rate
antibiot
resist
pathogen
mrsa
lower
hospit
previous
publish
report
lower
ni
report
test
sentri
antimicrobi
surveil
program
howev
despit
carbapenem
activ
antimicrobi
acinetobact
speci
increas
develop
signific
carbapenem
resist
among
acinetobact
speci
report
present
studi
averag
percentag
baumannii
isol
resist
imipenem
rate
icu
patient
irab
dai
rapidli
rise
among
enterobacteriacea
e
coli
k
pneumonia
e
coli
signific
increas
find
reveal
resist
gramneg
bacteria
increas
develop
requir
close
monitor
asid
fact
dai
import
prognost
factor
mortal
sever
previou
studi
shown
mortal
rate
attribut
dai
time
higher
attribut
infect
studi
support
find
publish
report
present
studi
multipl
regress
analysi
indic
patient
dai
compar
patient
hai
significantli
increas
likelihood
mortal
p
moreov
annual
mortal
rate
cauti
clabsi
signific
chang
period
result
may
caus
chanc
studi
period
chang
substanti
term
medic
care
novelti
medic
technolog
patient
diseas
sever
addit
find
use
multipl
regress
analysi
approach
adjust
covari
addit
demograph
invas
devic
laboratori
investig
also
identifi
sever
ill
use
apach
ii
score
predictor
mortal
result
indic
hazard
mortal
associ
increas
score
patient
die
dai
infect
usual
alreadi
sever
ill
exist
ill
rather
dai
often
main
caus
death
thu
import
prognost
factor
sever
ill
result
increas
likelihood
mortal
also
found
patient
blood
creatinin
mgdl
highest
risk
group
die
exclud
endogen
effect
reason
may
mani
patient
group
receiv
hemodialysi
cvc
insert
rate
dai
type
decreas
period
decreas
maintain
vap
similarli
decreas
ni
dai
report
epidemiolog
studi
effect
control
respiratori
tract
infect
antibiot
stewardship
implement
traffic
control
practic
improv
adher
hand
hygien
contact
precaut
practic
result
sever
acut
respiratori
syndrom
sar
pandem
well
decreas
rate
resist
mrsa
irpa
irab
might
account
decreas
limit
present
studi
note
studi
perform
singl
medic
center
howev
result
could
provid
hospit
part
teach
research
mission
studi
retrospect
nineyear
survey
might
potenti
bias
analysi
chang
infect
rate
mortal
rate
must
consid
whether
chang
popul
advanc
laboratori
diagnost
techniqu
chang
exposur
risk
factor
microbi
cultur
factor
lead
increas
decreas
rate
howev
occur
outbreak
dai
studi
period
except
sar
outbreak
present
secular
trend
dai
institut
northern
taiwan
great
achiev
infect
control
surveil
program
mainten
low
dai
incid
despit
high
ratio
incid
dai
decreas
incid
vap
remain
low
rate
antimicrobi
resist
three
common
pathogen
caus
vap
decreas
implement
infect
control
traffic
control
bundl
improv
adher
hand
hygien
practic
antibiot
stewardship
impact
sar
pandem
adher
practic
might
explain
decreas
dai
incid
rate
antibiot
resist
studi
also
demonstr
dai
import
independ
prognost
factor
mortal
author
declar
compet
interest
yyc
particip
design
data
collect
analysi
draft
manuscript
lyc
particip
analysi
draft
manuscript
syl
pc
comment
draft
manuscript
syl
particip
data
collect
fdw
conceiv
project
particip
design
help
draft
manuscript
author
approv
final
manuscript
prepubl
histori
paper
access
http
